Eli Lilly Nederland B.V.
35 products tracked · names used in filings: Eli Lilly Nederland B.V.
Upcoming milestones
Foundayo (Orforglipron): expected EC decision
Estimated as CHMP opinion (2026-10-15) + 67 days, the standard Commission decision period. Not an official date. · Eli Lilly Nederland B.V. · source
Recent milestones
Foundayo (Orforglipron): CHMP positive opinion
Onswik (Insulin efsitora alfa): expected EC decision
Estimated as CHMP opinion (2026-06-25) + 67 days, the standard Commission decision period. Not an official date. · Eli Lilly Nederland B.V. · source
Onswik (Insulin efsitora alfa): CHMP positive opinion
Inluriyo (imlunestrant) approved in the EU
Marketing authorisation to Eli Lilly Nederland B.V.; Additional monitoring · source
Inluriyo (imlunestrant): CHMP positive opinion
Eli Lilly Nederland B.V.; Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Onswik Insulin efsitora alfa | Opinion | |
| 🇪🇺 | Arxxant ruboxistaurin | Application withdrawn | |
| 🇪🇺 | Bamlanivimab and etesevimab for COVID-19 bamlanivimab;Etesevimab | Withdrawn from rolling review | |
| 🇪🇺 | Foundayo Orforglipron | Opinion | |
| 🇪🇺 | Inluriyo imlunestrant | Authorised | 2026-01-09 |
| 🇪🇺 | Kisunla donanemab | Authorised | 2025-09-24 |
| 🇪🇺 | Tauvid flortaucipir (18F) | Authorised | 2024-08-22 |
| 🇪🇺 | Jaypirca pirtobrutinib | Authorised | 2023-10-30 |
| 🇪🇺 | Omvoh mirikizumab | Authorised | 2023-05-26 |
| 🇪🇺 | Mounjaro tirzepatide | Authorised | 2022-09-15 |
| 🇪🇺 | Rayvow lasmiditan | Authorised | 2022-08-17 |
| 🇪🇺 | Retsevmo selpercatinib | Authorised | 2021-02-11 |
| 🇪🇺 | Lyumjev (previously Liumjev) insulin lispro | Authorised | 2020-03-24 |
| 🇪🇺 | Emgality galcanezumab | Authorised | 2018-11-14 |
| 🇪🇺 | Verzenios abemaciclib | Authorised | 2018-09-26 |
| 🇪🇺 | Tadalafil Lilly tadalafil | Authorised | 2017-03-22 |
| 🇪🇺 | Olumiant baricitinib | Authorised | 2017-02-13 |
| 🇪🇺 | Lartruvo olaratumab | Revoked | 2016-11-09 |
| 🇪🇺 | Portrazza necitumumab | Withdrawn | 2016-02-15 |
| 🇪🇺 | Cyramza ramucirumab | Authorised | 2014-12-19 |
| 🇪🇺 | Duloxetine Lilly duloxetine | Authorised | 2014-12-08 |
| 🇪🇺 | Trulicity dulaglutide | Authorised | 2014-11-21 |
| 🇪🇺 | Abasaglar (previously Abasria) insulin glargine | Authorised | 2014-09-09 |
| 🇪🇺 | Amyvid florbetapir (18F) | Authorised | 2013-01-14 |
| 🇪🇺 | Adcirca (previously Tadalafil Lilly) tadalafil | Authorised | 2008-10-01 |
| 🇪🇺 | Cymbalta duloxetine | Authorised | 2004-12-17 |
| 🇪🇺 | Alimta pemetrexed | Authorised | 2004-09-20 |
| 🇪🇺 | Ariclaim duloxetine | Withdrawn | 2004-08-11 |
| 🇪🇺 | Yentreve duloxetine | Authorised | 2004-08-11 |
| 🇪🇺 | Forsteo teriparatide | Authorised | 2003-06-10 |
| 🇪🇺 | Cialis tadalafil | Authorised | 2002-11-12 |
| 🇪🇺 | Xigris drotrecogin alfa (activated) | Withdrawn | 2002-08-22 |
| 🇪🇺 | Liprolog insulin lispro | Authorised | 2001-08-01 |
| 🇪🇺 | Optruma raloxifene | Withdrawn | 1998-08-05 |
| 🇪🇺 | Humalog insulin lispro | Authorised | 1996-04-30 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.